IMPROVE observational program: safety and effectiveness of biphasic insulin aspart 30 in routine clinical practice. Overview of starting characteristics of the Russian patient cohort
AIM: To analyse starting characteristics of the Russian patient cohort included in the IMPROVE observational program with reference to its demographiccomposition and clinical features of the disease in patients allocated to different groups depending on previous treatment, reason for prescribing DiA...
Guardado en:
Autores principales: | Marina Vladimirovna Shestakova, Akill Ballan |
---|---|
Formato: | article |
Lenguaje: | EN RU |
Publicado: |
Endocrinology Research Centre
2009
|
Materias: | |
Acceso en línea: | https://doaj.org/article/5559038c5c01444990377c7ad5906eb9 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Therapy with biphasic insulin aspart 30/70 (NovoMix 30) improves glycemic control in patients with type 2 diabetes mellitus: resultsfrom a Russian cohort of IMPROVE observational program designed to study safety and efficiency of biphasic insulin aspart 30 inroutine clinical practice
por: Marina Vladimirovna Shestakova, et al.
Publicado: (2010) -
Insulin therapy and body weight: benefits of biphasic human insulin analogue NovoMix 30
por: Elena Viktorovna Surkova
Publicado: (2013) -
Dvukhfaznyy insulin aspart 30 plyusmetformin: effektivnaya kombinatsiyadlya lecheniya sakharnogo diabeta 2 tipa
por: M Kvapil, et al.
Publicado: (2006) -
Effektivnost' i bezopasnost' dvukhfaznogo insulina Aspart 30 po dannym lecheniya patsientov s sakharnym diabetom 2 tipa v Rossiyskoy Federatsii: rezul'taty mnogotsentrovogo nablyudatel'nogo issledovaniya
por: Marina Vladimirovna Shestakova, et al.
Publicado: (2007) -
Insulin degludec/insulin aspart is the first co-formulation of basal and prandial insulin analogues
por: Ivan Ivanovich Dedov, et al.
Publicado: (2014)